Skip to main content
SpringerLink
Log in

Cyclophosphamide-based mobilisation less costly

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Costs (2012 values) were calculated per patient in both groups (including all reimbursable procedures, hospitalisations and costs of all medications during mobilisation).

Reference

  • Awan F, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplantation : 15 Apr 2013. Available from: URL: http://dx.doi.org/10.1038/bmt.2013.52

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cyclophosphamide-based mobilisation less costly. PharmacoEcon Outcomes News 678, 5 (2013). https://doi.org/10.1007/s40274-013-0390-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0390-x

Search

Navigation